bryostatin
Small moleculeexperimental
Bryostatins are a group of macrolide lactones from the marine organism Bugula neritina that were first collected and provided to JL Hartwell’s anticancer drug discovery group at the National Cancer Institute (NCI) by Jack Rudloe. Bryostatins are potent modulators of protein kinase C. They have been studied in clinical trials as anti-cancer agents, as anti-AIDS/HIV agents and in people with Alzheimer's disease. — Wikipedia
Clinical trial activity
44 trials · 32 clinical orgs · 0 marketing orgs
Phase 1
16
Phase 2
29
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 1996 (NCT00002725)
Timeline
Indications
Studied for
- Alzheimer Disease · Phase 2
- Anemia, Refractory · Phase 1
- Breast Neoplasms · Phase 2
- Burkitt Lymphoma · Phase 1
- Carcinoma, Renal Cell · Phase 2
- Colorectal Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Head and Neck Neoplasms · Phase 2
- Hemoglobinuria, Paroxysmal · Phase 1
- HIV Infections · Phase 1
- Intestinal Neoplasms · Phase 1
- Kidney Neoplasms · Phase 2
- Leukemia · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia-Lymphoma, Adult T-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 1
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 2
- Lymphoma, AIDS-Related · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 2
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Mantle-Cell · Phase 2
- Melanoma · Phase 1
- Multiple Myeloma · Phase 2
- Multiple Sclerosis · Phase 1
- Myelodysplastic Syndromes · Phase 2
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Stomach Neoplasms · Phase 2
- Thrombocytopenia · Phase 1
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- Protein kinase C alphaAGONIST
PRKCA agonist
Chemistry & pharmacology
Loading structure…
SMILES
CCC/C=C/C=C/C(=O)O[C@H]1/C(=C/C(=O)OC)C[C@H]2C[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H]3C[C@H](OC(C)=O)C(C)(C)[C@](O)(C[C@@H]4C/C(=C/C(=O)OC)C[C@H](/C=C/C(C)(C)[C@]1(O)O2)O4)O3- Mol. weight
- 905.04 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBryostatin ↗
- ChEMBLCHEMBL449158 ↗
Also known as
- bryostatin
- bryostatin
- bryostatin 1
- bryostatin 1
- bryostatin-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06190912 | Phase 1 | Jun 26, 2024 | The Cleveland Clinic |
| NCT04538066 | Phase 2 | Aug 30, 2020 | National Institute on Aging (NIA), National Institutes of Health (NIH), Petros Pharmaceuticals |
| NCT03560245 | Phase 2 | Jun 20, 2018 | Petros Pharmaceuticals, Worldwide Clinical Trials |
| NCT02431468 | Phase 2 | Nov 1, 2015 | Petros Pharmaceuticals |
| NCT02269605 | Phase 1 | Sep 1, 2014 | Universidad Complutense de Madrid |
| NCT02221947 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2014 | Blanchette Rockefeller Neurosciences Insitute, California Clinical Trials, Petros Pharmaceuticals |
| NCT00606164 | Phase 2 | Apr 1, 2008 | Blanchette Rockefeller Neurosciences Insitute, West Virginia University |
| NCT00112476 | Phase 1 | Mar 1, 2005 | National Cancer Institute (NCI), Temple University |
| NCT00087425 | Phase 2 | Jul 1, 2004 | National Cancer Institute (NCI), National Institute on Aging (NIA) |
| NCT00058305 | Phase 2 | Mar 1, 2003 | Case Western Reserve University, National Cancer Institute (NCI) |
| NCT00032188 | Phase 2 | Jan 1, 2002 | National Cancer Institute (NCI), University of Chicago |
| NCT00031694 | Phase 2 | Jan 1, 2002 | National Cancer Institute (NCI), Yeshiva University |
| NCT00022555 | Phase 1 | Nov 1, 2001 | AIDS Malignancy Consortium, National Cancer Institute (NCI) |
| NCT00017342 | Phase 2 | Jul 1, 2001 | National Cancer Institute (NCI), Virginia Commonwealth University |
| NCT00012376 | Phase 1 | Mar 1, 2001 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT00006389 | Phase 2 | Oct 1, 2000 | National Cancer Institute (NCI), University of Southern California |
| NCT00006942 | Phase 2 | Oct 1, 2000 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT00006022 | Phase 1 | Sep 1, 2000 | National Cancer Institute (NCI), Virginia Commonwealth University |
| NCT00005965 | Phase 2 | Aug 1, 2000 | Icahn School of Medicine at Mount Sinai, National Cancer Institute (NCI) |
| NCT00006081 | Phase 2 | Jun 1, 2000 | National Cancer Institute (NCI), University of Texas at Houston |
Showing 20 of 44 trials
Page 1 / 3
Organizations
Research & Development (32)
32 organizations
Page 1 / 2